Literature DB >> 7558953

Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel.

J van Rijn1, J van den Berg, O W Meijer.   

Abstract

PURPOSE: This study was performed to determine the effects of a continuous exposure to paclitaxel (taxol) in combination with fractionated irradiation on cell proliferation and survival. METHODS AND MATERIALS: Human lung carcinoma cells (SW1573) were given a daily treatment with 3 Gy of x-rays during 5 days in the continuous presence of 5 nM taxol. The surviving fraction and the total number of cells were determined every 24 h before and immediately after irradiation.
RESULTS: Irradiation with 5 x 3 Gy and 5 nM taxol cause approximately the same inhibition of cell proliferation. In combination these treatments have an additional effect and the cell population increases no further after the first 24 h. Whereas the cells become more resistant to taxol after the first 24 h with a minimum survival of 42%, taxol progressively reduces the population of surviving cells in combination with x-rays when the number of fractions increases, up to 25-fold relative to irradiation alone. The enhancement effect of 5 nM taxol is likely to be attributed to an inhibition of the repopulation during fractionated irradiation and not to an increased radiosensitivity. Only after treatment with 10 or 100 nM taxol for 24 h, which is attended with a high cytotoxicity, is moderate radiosensitization observed.
CONCLUSION: Taxol, continuously present at a low concentration with little cytotoxicity, causes a progressive reduction of the surviving cell population in combination with fractionated irradiation, mainly by an inhibition of the repopulation of surviving cells between the dose fractions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558953     DOI: 10.1016/0360-3016(95)00216-l

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  The effect of paclitaxel on the radiosensitivity of gynecological tumor cells.

Authors:  M Rave-Fränk; H Meden; A Jäschke; A Tänzer; O Boghun; R Fietkau
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

2.  Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.

Authors:  Jun-Fang Liao; Qun Zhang; Xiao-Jing Du; Mei Lan; Shan Liu; Yun-Fei Xia; Xiu-Yu Cai; Wei Luo
Journal:  Cancer Commun (Lond)       Date:  2019-06-27

3.  A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.

Authors:  Yun Chen; Zhengfei Zhu; Weixin Zhao; Ling Li; Jinjun Ye; Chaoyang Wu; Huarong Tang; Qin Lin; Jiancheng Li; Yi Xia; Yunhai Li; Jialiang Zhou; Kuaile Zhao
Journal:  Radiat Oncol       Date:  2018-02-27       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.